Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model
In many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cel...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-05-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.12938 |
| _version_ | 1818716102829539328 |
|---|---|
| author | Sadiya Parveen Sumit Siddharth Laurene S. Cheung Alok Kumar Jessica Shen John R. Murphy Dipali Sharma William R. Bishai |
| author_facet | Sadiya Parveen Sumit Siddharth Laurene S. Cheung Alok Kumar Jessica Shen John R. Murphy Dipali Sharma William R. Bishai |
| author_sort | Sadiya Parveen |
| collection | DOAJ |
| description | In many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cells in the TME and spleen including myeloid‐derived suppressor cells (MDSCs) and tumor‐associated macrophages (TAMs) also express the IL‐4R, we hypothesized that selective depletion of IL‐4R‐bearing cells in TNBC would result in the direct killing of tumor cells and the depletion of immunosuppressive cells and lead to an enhanced antitumor response. To selectively target IL‐4R+ cells, we employed DABIL‐4, a fusion protein toxin consisting of the catalytic and translocation domains of diphtheria toxin fused to murine IL‐4. As anticipated, DABIL‐4 has potent cytotoxic activity against TNBC cells both in vitro and in vivo. We demonstrate in the murine 4T1 TNBC model that DABIL‐4 significantly reduces tumor growth, splenomegaly, and lung metastases. Importantly, we also show that the administration of DABIL‐4 results in the selective depletion of MDSCs, TAMs, and regulatory T cells in treated mice, with a concomitant increase in IFN‐γ+ CD8 effector T cells in the TME. Since the 4T1 antitumor activity of DABIL‐4 was largely diminished in IL‐4R knockout mice, we postulate that DABIL‐4 functions primarily as an immunotherapeutic by the depletion of MDSCs, TAMs, and regulatory T cells. NanoString analysis of control and treated tumors confirmed and extended these observations by showing a marked decline of mRNA transcripts that are associated with tumorigenesis and metastasis. In conclusion, we demonstrate that DABIL‐4 targeting of both tumor and immunosuppressive host cells likely represents a novel and effective treatment strategy for 4T1 TNBC and warrants further study. |
| first_indexed | 2024-12-17T19:13:56Z |
| format | Article |
| id | doaj.art-065aff525a494219bfd3fbcc76e116b8 |
| institution | Directory Open Access Journal |
| issn | 1574-7891 1878-0261 |
| language | English |
| last_indexed | 2024-12-17T19:13:56Z |
| publishDate | 2021-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | Molecular Oncology |
| spelling | doaj.art-065aff525a494219bfd3fbcc76e116b82022-12-21T21:35:47ZengWileyMolecular Oncology1574-78911878-02612021-05-011551330134410.1002/1878-0261.12938Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer modelSadiya Parveen0Sumit Siddharth1Laurene S. Cheung2Alok Kumar3Jessica Shen4John R. Murphy5Dipali Sharma6William R. Bishai7Department of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore MD USADepartment of Oncology Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Johns Hopkins University School of Medicine Baltimore MD USADepartment of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore MD USADepartment of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore MD USADepartment of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore MD USADepartment of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore MD USADepartment of Oncology Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Johns Hopkins University School of Medicine Baltimore MD USADepartment of Medicine Division of Infectious Diseases Johns Hopkins University School of Medicine Baltimore MD USAIn many solid tumors including triple‐negative breast cancer (TNBC), upregulation of the interleukin‐4 receptor (IL‐4R) has been shown to promote cancer cell proliferation, apoptotic resistance, metastatic potential, and a Th2 response in the tumor microenvironment (TME). Since immunosuppressive cells in the TME and spleen including myeloid‐derived suppressor cells (MDSCs) and tumor‐associated macrophages (TAMs) also express the IL‐4R, we hypothesized that selective depletion of IL‐4R‐bearing cells in TNBC would result in the direct killing of tumor cells and the depletion of immunosuppressive cells and lead to an enhanced antitumor response. To selectively target IL‐4R+ cells, we employed DABIL‐4, a fusion protein toxin consisting of the catalytic and translocation domains of diphtheria toxin fused to murine IL‐4. As anticipated, DABIL‐4 has potent cytotoxic activity against TNBC cells both in vitro and in vivo. We demonstrate in the murine 4T1 TNBC model that DABIL‐4 significantly reduces tumor growth, splenomegaly, and lung metastases. Importantly, we also show that the administration of DABIL‐4 results in the selective depletion of MDSCs, TAMs, and regulatory T cells in treated mice, with a concomitant increase in IFN‐γ+ CD8 effector T cells in the TME. Since the 4T1 antitumor activity of DABIL‐4 was largely diminished in IL‐4R knockout mice, we postulate that DABIL‐4 functions primarily as an immunotherapeutic by the depletion of MDSCs, TAMs, and regulatory T cells. NanoString analysis of control and treated tumors confirmed and extended these observations by showing a marked decline of mRNA transcripts that are associated with tumorigenesis and metastasis. In conclusion, we demonstrate that DABIL‐4 targeting of both tumor and immunosuppressive host cells likely represents a novel and effective treatment strategy for 4T1 TNBC and warrants further study.https://doi.org/10.1002/1878-0261.12938DABIL‐4diphtheria fusion toxinIL‐4Rmyeloid‐derived suppressor cellstriple‐negative breast cancertumor‐associated macrophages |
| spellingShingle | Sadiya Parveen Sumit Siddharth Laurene S. Cheung Alok Kumar Jessica Shen John R. Murphy Dipali Sharma William R. Bishai Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model Molecular Oncology DABIL‐4 diphtheria fusion toxin IL‐4R myeloid‐derived suppressor cells triple‐negative breast cancer tumor‐associated macrophages |
| title | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
| title_full | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
| title_fullStr | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
| title_full_unstemmed | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
| title_short | Therapeutic targeting with DABIL‐4 depletes myeloid suppressor cells in 4T1 triple‐negative breast cancer model |
| title_sort | therapeutic targeting with dabil 4 depletes myeloid suppressor cells in 4t1 triple negative breast cancer model |
| topic | DABIL‐4 diphtheria fusion toxin IL‐4R myeloid‐derived suppressor cells triple‐negative breast cancer tumor‐associated macrophages |
| url | https://doi.org/10.1002/1878-0261.12938 |
| work_keys_str_mv | AT sadiyaparveen therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT sumitsiddharth therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT laurenescheung therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT alokkumar therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT jessicashen therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT johnrmurphy therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT dipalisharma therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel AT williamrbishai therapeutictargetingwithdabil4depletesmyeloidsuppressorcellsin4t1triplenegativebreastcancermodel |